The medtech firm plans to launch its next flagship patch-pump in 2027, and its first fully closed loop system for Type 2 diabetes in 2028.

Chris Eubank Jr's rematch with Conor Benn has brought the controversial issue of how fighters make weight back into focus ...

A UK study finds that people with type 2 diabetes prefer flexible, easy-to-follow diets over strict low-calorie plans this ...

Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company ...

When a child is diagnosed with diabetes, it can feel overwhelming for parents, as everyday routines suddenly revolve around ...

EMERYVILLE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

Upper GI motility disorders—dysphagia, bloating, belching, and early satiety—are often frustrating for both patients and practitioners. While diagnoses like SIBO or GERD are commonly assigned, a ...

Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...

U.S. Secretary of State Mark Rubio accused the Rapid Support Forces of involvement in atrocities against civilians and held ...

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.